SULF-10 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sulf-10, and what generic alternatives are available?
Sulf-10 is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SULF-10 is sulfacetamide sodium. There are three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the sulfacetamide sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sulf-10
A generic version of SULF-10 was approved as sulfacetamide sodium by SANDOZ on October 18th, 1988.
Summary for SULF-10
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Patent Applications: | 4,047 |
Formulation / Manufacturing: | see details |
DailyMed Link: | SULF-10 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for SULF-10
US Patents and Regulatory Information for SULF-10
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SULF-10 | sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 080025-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |